Clinical trials: Campylobacter Infections
Campylobacter Infections, Irritable Bowel Syndrome
Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota
The principal research objective is to determine the impact of antibiotic use on the risk of developing long term bowel symptoms after infection with the germ Campylobacter.
- Trial name
- CERAMIC (NCT02040922)
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Nottingham
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Campylobacter Infections
Campylobacter Jejuni Challenge Model Development: Dose Ranging Study
The primary objective of this study is to establish a human Campylobacter jejuni infection model with the following characteristics: 1. Safe application 1.
- Trial name
- NCT00434798
- Testing
- Campylobacter jejuni strains CG8421 and BH-01-0142
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Campylobacter Infections
Campylobacter Spp. Bone and Joint Infection: a Retrospective Cohort Study
Campylobacter bacteria, a Gram-negative bacillus commensal in the digestive tract of many animals and mainly responsible for human infections with digestive origins, has been little studied in the field of osteoarticular…
- Trial name
- Campylo-BJI (NCT06425250)
- Testing
- Management, progression and risk factors for failure of BJI caused by Campylobacter spp., Description of the evolution and risk factors for failure of osteoarticular infections caused by Campylobacter spp.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Soil-transmitted Helminthiasis, Schistosomiasis
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
NIDIAG is an international collaboration on integrated diagnosis-treatment platforms, funded by the European Commission (EC). NIDIAG aims to develop an improved, patient-centred system for delivering primary health care in…
- Conditions
- Soil-transmitted Helminthiasis, Schistosomiasis, Strongyloidiasis, Shigellosis
- Trial name
- NIDIAGDigest (NCT02105714)
- Testing
- Stool culturing for pathogenic bacteria, Kato-Katz technique, Baermann technique
- Where
- 7 sites in Côte d’Ivoire, Indonesia and 2 more
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Swiss Tropical & Public Health Institute
Campylobacter Infection
ACE393-103 Vaccination Challenge Study
The purpose of this study is to determine whether ACE393 vaccination can protect against Campylobacteriosis in a challenge model.
- Trial name
- ACE393-103VC (NCT00859716)
- Testing
- ACE393
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- TD Vaccines A/S
Campylobacter Infections
Recurrent Campylobacter Bacteraemia in Immunocompromised Patients
Some rare cases of recurrent Campylobacter bacteraemia (RCB) exist with relapses months to years after an effective treatment and a negativation of all bacterial samples.
- Trial name
- CABARET (NCT06432777)
- Testing
- Characteristics of patients and Campylobacter bacteraemia episodes
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Hospices Civils de Lyon
Campylobacter Jejuni Infection
Safety and Pharmacokinetic Study of LMN-101 in Healthy Volunteers
This will be a randomized, double-blind, placebo-controlled, dose-escalation study of 3 dose levels of LMN-101. Healthy volunteers will take LMN-101 or placebo orally either as a single dose or at one of three dose levels three…
- Trial name
- NCT04098263
- Testing
- LMN-101
- Where
- Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Dysentery, Diarrhea
Efficacy of Rifaximin in Preventing Campylobacteriosis
This study is a randomized, double-blinded, placebo-controlled, in-patient trial evaluating the prophylactic efficacy of rifaximin against campylobacteriosis following challenge with C. jejuni.
- Conditions
- Dysentery, Diarrhea, Enteric Campylobacteriosis
- Trial name
- NCT02280044
- Testing
- Rifaximin intervention
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Stunting, Malnutrition; Protein
Protein Plus: Improving Infant Growth Through Diet and Enteric Health
This cluster-randomized controlled trial is designed to address linear growth faltering in 6-12-mo-old Bangladesh infants through a proof-of-concept package of interventions to a) increase intake of high quality protein and b)…
- Conditions
- Stunting, Malnutrition; Protein, Enteric Pathogens, Campylobacter Infections
- Trial name
- JiVitA-6 (NCT03683667)
- Testing
- Azithromycin Oral Product, Protein Supplement, Isocaloric Supplement
- Where
- Bangladesh
- Volunteers
- 5,283 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Campylobacter Infections
LMN-101 in a Campylobacter Human Challenge Model
Randomized, double-blind, placebo-controlled, single dose regimen study of LMN-101 followed by Campylobacter jejuni challenge. Subjects will initially, after documentation of informed consent, begin taking their assigned LMN-101…
- Trial name
- NCT04182490
- Testing
- LMN-101
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
Campylobacter Infections
Campylobacter Jejuni Challenge Model Development: Assessment of Homologous Protection
The goal of this research is to continue to develop a model of infection with Campylobacter jejuni, a bacterium that causes food and water-borne disease (mainly diarrhea).
- Trial name
- NCT01048112
- Testing
- Campylobacter jejuni strain CG8421
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Vermont
Campylobacter Infection
Safety and Immunogenicity of CJCV2 With and Without ALFQ
This is a randomized, double-blind, dose-escalating, outpatient trial in a total of approximately 60 subjects, assigned to 3 cohorts (20 subjects per cohort).
- Trial name
- NCT05500417
- Testing
- ALFQ, CJCV2
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Campylobacter Infection
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant.
- Trial name
- CJCV1-01 (NCT02067676)
- Testing
- Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Campylobacter Infections, Irritable Bowel Syndrome
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Some people develop chronic abdominal pain with diarrhea or constipation after an episode of acute bacterial gastroenteritis. These symptoms can be consistent with post-infectious irritable bowel syndrome (IBS) and can last long…
- Trial name
- NCT03266068
- Testing
- DNA Analysis of Blood Sample, Flexible sigmoidoscopy with colonic biopsies, Small bowel and colonic gastrointestinal permeability
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Campylobacter Infections, Bone Diseases, Infectious
Retrospective Study of Bone Infection Due to Campylobacter Spp
Only 24 cases of Campylobacter bone and joint infection (BJI) have been reported worldwide between 1955 and 2008. Between 2010 and 2012, 7 cases were observed in two University hospitals in France.
- Trial name
- CAMPYLO (NCT02884752)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Brest
Irritable Bowel Syndrome
Mucosal and Microbiota Changes During Acute Campylobacteriosis
Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as…
- Trial name
- NCT03223077
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic